Last reviewed · How we verify
NCT04835623
CEQUA for Sjogren's Syndrome Dry Eye
Phase 4 trial testing Cyclosporine 0.09% Ophthalmic Solution in Dry Eye in 50 participants. Completed in 21 March 2024.
21 March 2024
Quick facts
| Lead sponsor | Center for Ophthalmic and Vision Research, LLC |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 21 June 2021 |
| Primary completion | 21 March 2024 |
| Estimated completion | 21 March 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cyclosporine 0.09% Ophthalmic Solution — full drug profile →
Conditions studied
- Dry Eye — all drugs for Dry Eye →
- Dry Eye Syndromes — all drugs for Dry Eye Syndromes →
- Sjogren's Syndrome — all drugs for Sjogren's Syndrome →
Sponsor
Center for Ophthalmic and Vision Research, LLC — full company profile →
Who can join
Adults 18 to 70, any sex, with Dry Eye or Dry Eye Syndromes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to show that CEQUA (cyclosporine 0.09% ophthalmic solution) improves symptoms of dry eye disease in a population of patients with Sjogren's Syndrome diagnosis.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Dry eye syndrome: comprehensive etiologies and recent clinical trials.
Huang R, Su C, Fang L, Lu J, et al · · 2022 · cited 52× · PMID 35678897 · DOI 10.1007/s10792-022-02320-7 -
Therapeutic Targets in the Management of Dry Eye Disease Associated with Sjögren's Syndrome: An Updated Review of Current Insights and Future Perspectives.
Almulhim A. · · 2024 · cited 2× · PMID 38542002 · DOI 10.3390/jcm13061777
Verify or expand the search:
- PubMed search for NCT04835623
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dry Eye
Currently open trials in the same condition.
- NCT07366944 — PCOS and Problem of Eye Dryness: Is There a Benefit From Lifetyle Changes · NA · recruiting
- NCT07329712 — Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy · recruiting
- NCT07266948 — Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work · Phase 4 · recruiting
- NCT07298811 — Preliminary Clinical Study of the Effectiveness and Safety of Ocular Surface Microbiota Transplantation in the Treatment · Phase 1, PHASE2 · recruiting
- NCT07135193 — Evaluation of the Protective Effects of Cordyceps Cicadae on Visual Function and Anti-Fatigue Performance in Esports Ath · NA · active not recruiting
Other Center for Ophthalmic and Vision Research, LLC trials
Trials by the same sponsor.
- NCT05161208 — OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04835623 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Center for Ophthalmic and Vision Research, LLC
- Last refreshed: 16 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04835623.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing